Enteralia Bioscience Acquires TFarma, Expands in Italy's Nutraceutical Market

Enteralia Bioscience SRL has announced the acquisition of TFarma, a company specializing in nutraceuticals and medical devices in Italy. This move marks a significant step in Enteralia's expansion within the Italian market, a key sector in Europe.

The acquisition brings Enteralia access to TFarma's network of over 20 medical representatives, particularly skilled in gynecology and gastroenterology. Integrating TFarma's strong product portfolio is expected to enhance Enteralia's growth.

Enteralia is also set to expand its sales network, underpinned by new products from Nemysis Limited, its parent company. These efforts aim to boost revenue and profits significantly.

Enteralia plans to invest in TFarma's team, acknowledging their importance in the company's continued success. The shared focus on women's health and gastroenterology underscores Enteralia's strategy for future growth.